Blog
RSS FeedPosted by Michael Wonder on 24 Nov 2023
Ritlecitinib tosylate for the treatment of people with alopecia areata
24 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 23 Nov 2023
Cedazuridine with decitabine for patients with untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
23 November 2023 - NICE is unable to make a recommendation on the use of cedazuridine with decitabine (Inaqovi) for the ...
Posted by Michael Wonder on 22 Nov 2023
Zanubrutinib for the treatment of patients with chronic lymphocytic leukaemia (final guidance)
22 November 2023 - NICE has published final evidence-based recommendations on the use of zanubrutinib (Brukinsa) for the treatment of ...
Posted by Michael Wonder on 20 Nov 2023
Landmark medicines deal to boost nation’s health, save NHS £14 billion, and support research investment
20 November 2023 - Pro-innovation and pro-competition agreement will introduce a new mechanism to support lower industry payment rates for more ...
Posted by Michael Wonder on 20 Nov 2023
NICE gets ready to assess new dementia treatments
20 November 2023 - NICE’s methods and processes for evaluating new treatments for use in the NHS are appropriate for the ...
Posted by Michael Wonder on 15 Nov 2023
Lutetium Lu 177 vipivotide tetraxetan for the treatment of patients with metastatic PSMA positive hormone-relapsed prostate cancer after two or more treatments
15 November 2023 - NICE has published final evidence-based recommendations on the use of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) ...
Posted by Michael Wonder on 07 Nov 2023
NICE launches refreshed support service for life sciences industry
6 November 2023 - NICE has today launched its refreshed support service for the life sciences sector, NICE Advice. ...
Posted by Michael Wonder on 04 Nov 2023
Elexacaftor with tezacaftor and ivacaftor, tezacaftor with ivacaftor and lumacaftor with ivacaftor for the treatment of patients with cystic fibrosis
3 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 02 Nov 2023
Ivosidenib for the treatment of patients with advanced IDH1 mutation positive cholangiocarcinoma after at least one line of treatment
2 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Nov 2023
Epcoritamab for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
1 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Nov 2023
Empagliflozin for the treatment of adults with chronic heart failure with preserved or mildly reduced ejection fraction
1 November 2023 - NICE has published final evidence-based recommendations on the use of empagliflozin (Jardiance) for the treatment of ...
Posted by Michael Wonder on 01 Nov 2023
Cabozantinib maleate for previously treated adults with advanced differentiated thyroid cancer that is unsuitable for or refractory to radioactive iodine
1 November 2023 - NICE has published final evidence-based recommendations on the use of cabozantinib maleate (Cabometyx) for previously treated ...
Posted by Michael Wonder on 31 Oct 2023
NICE launches first modular update to its methods and processes
31 October 2023 - NICE’s methods and processes now include a proportionate approach to technology appraisals, and a new way of ...
Posted by Michael Wonder on 26 Oct 2023
Olipudase alfa for the treatment of patients with acid sphingomyelinase deficiency (Niemann-Pick disease type B and AB)
26 October 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 26 Oct 2023
First NICE recommended treatment for Parkinson’s set to benefit hundreds
26 October 2023 - Around 900 adults with advanced Parkinson’s are set to benefit from new treatment foslevodopa–foscarbidopa after NICE approved ...